Katalin Karikó

Katalin Karikó. A Hungarian-American biochemist whose decades of foundational research on messenger RNA (mRNA) were instrumental in the rapid development of the first effective COVID-19 vaccines. Her work, conducted alongside colleague Drew Weissman, solved critical immunological hurdles by modifying nucleosides within mRNA, enabling its therapeutic use. For this achievement, she was awarded the Nobel Prize in Physiology or Medicine in 2023, cementing her legacy as a pivotal figure in vaccinology and biotechnology.

Early life and education

Katalin Karikó was born in Szolnok, Hungary, and grew up in the small town of Kisújszállás. Her early interest in science was nurtured by her father, a butcher, who encouraged her observations of natural processes. She attended the University of Szeged, where she earned a Bachelor of Science degree in biology in 1978 and subsequently a PhD in biochemistry in 1982, focusing on RNA research. Her doctoral work was conducted at the Biological Research Centre in Szeged, a leading institute of the Hungarian Academy of Sciences. Following her PhD, she held a postdoctoral position at the same institution until 1985, when she emigrated with her family to the United States amid challenging economic conditions in Hungary.

Research on mRNA and career challenges

Upon moving to the United States, Karikó faced significant professional adversity, struggling to secure stable funding for her ambitious research into mRNA as a therapeutic tool. She held a postdoctoral fellowship at Temple University before joining the University of Pennsylvania in 1989. For years, her grant proposals were repeatedly rejected, and she was eventually demoted from her faculty position, viewed by some as pursuing a scientific dead end. A pivotal collaboration began in 1997 with immunologist Drew Weissman at the University of Pennsylvania. Together, they discovered that dendritic cells recognized in vitro transcribed mRNA as a foreign threat, triggering an unwanted inflammatory response. Their seminal 2005 breakthrough, published in the journal Immunity, demonstrated that replacing uridine with pseudouridine in the mRNA strand effectively evaded this immune detection, a modification that proved crucial for therapeutic application.

Development of mRNA vaccines for COVID-19

The nucleoside-modified mRNA platform developed by Karikó and Weissman laid the essential groundwork for the rapid vaccine response to the SARS-CoV-2 pandemic. In 2013, Karikó joined BioNTech, a German biotechnology company, as a senior vice president, where she helped advance the technology. When the COVID-19 pandemic began, both BioNTech (in partnership with Pfizer) and Moderna utilized this modified mRNA approach to encode the spike protein of the coronavirus. The resulting BNT162b2 and mRNA-1273 vaccines demonstrated exceptional efficacy in clinical trials and received Emergency Use Authorization from the U.S. Food and Drug Administration in late 2020. Their global deployment marked the first widespread use of mRNA technology and is credited with saving millions of lives, validating Karikó's lifelong dedication to the field.

Awards and recognition

Following the success of the COVID-19 vaccines, Karikó received an extraordinary cascade of the world's most prestigious scientific and public honors. In 2021, she and Weissman were awarded the Lasker-DeBakey Clinical Medical Research Award, often a precursor to the Nobel, and the Breakthrough Prize in Life Sciences. In 2022, she was named to the Forbes list of the World's 100 Most Powerful Women and received awards such as the Japan Prize and the Princess of Asturias Award for Technical and Scientific Research. The pinnacle came in 2023 when she and Weissman were jointly awarded the Nobel Prize in Physiology or Medicine. She has also been elected a member of the National Academy of Sciences and the German National Academy of Sciences Leopoldina.

Personal life

Katalin Karikó is married to Béla Francia, and they have one daughter, Susan Francia, a two-time Olympic gold medalist in rowing for the United States. Karikó has often cited the resilience and work ethic required to balance her demanding research career with family life, especially during years of professional instability. Her personal story of perseverance, from a small town in Hungary to the global stage of the Nobel Prize, has made her an inspirational figure in science. She maintains strong ties to her native country and is a role model for scientists worldwide facing skepticism and funding challenges.

Category:Hungarian biochemists Category:American biochemists Category:Nobel laureates in Physiology or Medicine Category:University of Szeged alumni Category:BioNTech people